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LESSONS LEARNED
• Motivating patients to enroll in chemopreventive studies is challenging.
• Chemoprevention with toxic drugs is not feasible.
ABSTRACT
Background. LKB1 mutations are the underlying genetic
abnormality causing Peutz-Jeghers syndrome (PJS) and are a
potential target for everolimus. In this phase II study, the efﬁcacy
of everolimus on polyp and tumor growth in PJS patients was
investigated.
Methods. Adult patients with a proven LKB1 mutation and who
were suitable for everolimus treatment were included in two
different PJS cohorts: (a) patients with unresectable malignan-
cies and (b) patients with high-risk polyps. Treatment in both
groups was oral everolimus, 10 mg daily. Response rates were
primary endpoints for both cohorts.
Results. Between October 2011 and April 2016, only two
patients were enrolled, one in each cohort. A 49-year-old
patient with advanced pancreatic cancer in cohort 1 was
progressive after 2 months. A 52-year-old male patient in
cohort 2 experienced severe toxicity and refused treatment
after 4 months, even though endoscopy suggested stabili-
zation of polyps. Adverse events included dental inﬂamma-
tions, mucositis, and rash. In 2016, the trial was aborted
for lack of accrual, despite extensive accrual efforts in an
area where PJS is highly prevalent and care is highly
centralized.
Conclusion. Due to accrual problems, no conclusions can be
drawn about the value of everolimus in PJS treatment, ques-
tioning the feasibility of this agent for chemoprevention. The
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DISCUSSION
Peutz-Jeghers syndrome is caused by a mutation in the LKB1
gene, a tumor suppressor gene located on chromosome 19.
This mutation results in a decreased inhibition of mammalian
target of rapamycin (mTOR), with uncontrolled cell growth as a
result, manifesting as intestinal polyps (Fig. 1) and malignan-
cies. Oral selective mTOR inhibitors such as rapamycin and
everolimus have been successfully used in several exploratory
studies [1, 2]. The report of a successful treatment of a PJS
patient with pancreatic cancer with everolimus was the starting
point for a more comprehensive study: the EVAMP trial [3].
Our hypothesis was that treating PJS patients with everolimus
would result in reduced growth of intestinal polyps and tumors.
In 2011, researchers from the University of Utah initiated a sim-
ilar study on the role of chemoprevention agents in PJS, which
was stopped prematurely because of poor accrual [4].
Due to the rare nature of the disease, the intent was to start
with a pilot study including 15 patients, executed in the two larg-
est PJS centers in The Netherlands (Academic Medical Center,
Amsterdam, and Erasmus Medical Center, Rotterdam). To obtain
relevant information about activity of everolimus, we selected a
high-risk population consisting of patients with either fast-growing
gastric or small bowel polyps requiring therapeutic enteroscopy at
least once every 2 years with resection of >4 polyps larger than
15mm, or patients suffering from PJS-related malignancies.
Correspondence: Dr. Heinz-Josef Kl€umpen, Department of Medical Oncology, Academic Medical Center, Cancer Center Amsterdam, Meibergdreef
9, 1105AZ, Amsterdam, The Netherlands. Telephone: 3-120-566-5955; e-mail: h.klumpen@amc.uva.nl Received September 4, 2017; accepted for
publication December 3, 2017; published Online First on January 25, 2018.Oc AlphaMed Press; the data published online to support this summary
is the property of the authors. http://dx.doi.org/10.1634/theoncologist.2017-0682
TheOncologist 2018;23:399–e33 www.TheOncologist.com Oc AlphaMed Press 2018
Clinical Trial Results
 by guest on M
ay 29, 2019
http://theoncologist.alpham
edpress.org/
D
ow
nloaded from
 
Despite the clear study design, the selection of high-risk
patients, and well-targeted medication, our study met
some major obstacles. First, it turned out to be very difﬁcult
to ﬁnd enough relevant patients, and secondly, the chosen
treatment turned out to have both poor tolerability and
(although in only one patient) a disappointing lack of efﬁ-
cacy. Even in two areas where PJS is highly prevalent (The
Netherlands and Utah), researchers were not even close to
reaching enough patients to perform a trial. Also, extensive
accrual efforts, including the provision of additional trial
information in national medical journals and during two
patient information days in the accrual period, did not lead
to increased patient participation. We presume that the
currently existing intense surveillance programs do already
diminish the rate of symptomatic polyps and malignancies
and, therefore, are considered by patients to be efﬁcacious,
which probably hampers the willingness of these patients
to enroll in chemoprevention treatment studies. In addi-
tion, everolimus often induces cumbersome side effects,
which further decreases long-term use in prevention.
Furthermore, the need for dose reduction in both The
Netherlands and Utah conﬁrmed the poor tolerability of
everolimus therapy. Therefore, it is not surprising that both
experiences raise the question of whether use of this drug
for chemoprevention in PJS patients is feasible. Potential
future options are a lower dose of everolimus, or another
targeted agent.
TRIAL INFORMATION
Disease Advanced cancer
Disease Peutz-Jeghers syndrome
Stage of Disease/Treatment Prevention
Prior Therapy None
Type of Study - 1 Phase II
Type of Study - 2 Single arm
Primary Endpoint Overall response rate
Secondary Endpoint Toxicity
Investigator’s Analysis Poorly tolerated/not feasible
DRUG INFORMATION FOR PHASE II ADVANCED MALIGNANCIES
Drug 1
Generic/Working Name Everolimus
Trade Name Aﬁnitor
Company Name Novartis
Dose 10 mg per ﬂat dose
Route p.o.
PATIENT CHARACTERISTICS FOR PHASE II ADVANCED MALIGNANCIES
Number of Patients, Male 1
Number of Patients, Female 0
Age Median (range): 48
Number of Prior Systemic Therapies Median (range): 0
Performance Status: ECOG 0 — 1
1 — 0
2 — 0
3 — 0
Unknown —
Figure 1. A Peutz-Jeghers polyp of the small intestine with arboriz-
ing smooth muscle ﬁbers and non-neoplastic epithelium.
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PATIENT CHARACTERISTICS FOR PHASE II HIGH-RISK POLYPS
Number of Patients, Male 1
Number of Patients, Female 0
Age Median (range): 53
Number of Prior Systemic Therapies Median (range): 0
Performance Status: ECOG 0 — 0
1 — 1
2 — 0
3 — 0
Unknown —
PRIMARYASSESSMENT METHOD FOR PHASE II ADVANCED MALIGNANCIES
Title Total patient population
Number of Patients Screened 1
Number of Patients Enrolled 1
Number of Patients Evaluable for Toxicity 1
Number of Patients Evaluated for Efﬁcacy 0
Evaluation Method RECIST 1.1
Response Assessment PD n5 1 (100%)
(Median) Duration Assessments PFS 7 weeks
(Median) Duration Assessments TTP 7 weeks
(Median) Duration Assessments OS 6 months
(Median) Duration Assessments Duration of Treatment 7 weeks
PRIMARYASSESSMENT METHOD FOR PHASE II HIGH-RISK POLYPS
Title Total patient population
Number of Patients Screened 1
Number of Patients Enrolled 1
Number of Patients Evaluable for Toxicity 1
Number of Patients Evaluated for Efﬁcacy 1
Evaluation Method RECIST 1.1
Response Assessment SD n5 1 (100%)
(Median) Duration Assessments PFS 8 months
(Median) Duration Assessments Response Duration 8 months
(Median) Duration Assessments Duration of Treatment 4 months
Adverse Events: Phase II Advanced Malignancies None
Adverse Events: Phase II High-Risk Polyps Root cavity inﬂammation, three times
ASSESSMENT, ANALYSIS, AND DISCUSSION
Completion Study terminated before completion
Terminated Reason Did not fully accrue
Investigator’s Assessment Poorly tolerated/not feasible
Mutation spectrum: Peutz-Jeghers syndrome (PJS) is an
autosomal dominant condition characterized by multiple
hamartomatous polyps of the gastrointestinal tract, the pres-
ence of mucocutaneous hyperpigmentation, and an elevated
lifetime risk to develop cancer, varying between 37% and 93%
[1]. The genetic abnormality responsible for the syndrome is a
mutation in the LKB1/STK11 gene, which maps to 19p13 [2].
This LKB1/STK11 gene activates adenine monophosphate-
activated protein kinase, a necessary element in cell metabo-
lism that is required for maintaining energy homeostasis, which
in turn activates tumor suppressors tuberous sclerosis complex
1 and 2, leading to mammalian target of rapamycin (mTOR)
inhibition. Two well-characterized downstream targets of mTOR
are S6 kinase and eukaryotic translation initiation factor 4E-
binding protein 1. In genetic analysis of PJS families, around 150
different mutations in the LKB1 gene have been found, ranging
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from truncation to missense mutations [3, 4]. The kind of muta-
tion does not clearly correlate with the disease course, although
loss of heterozygosity is observed more frequently in PJS carcino-
mas than in PJS hamartomas. No data on speciﬁc LKB1 mutations
and the sensitivity tomTOR inhibition is available.
Suitability of everolimus: Elevated levels of phospho-S6
(pS6) kinase and pS6 are detected in the polyps from LKB1 1/
2 mice, suggesting that hyperactivation of mTOR signaling
accounts for the development of the PJS-characteristic hamar-
tomatous lesions. These observations suggested that mTOR
inhibitors such as rapamycin and its analogues could be useful
for the treatment of polyps arising from patients with PJS. Wei
et al. investigated in 2008 the beneﬁt of mTOR inhibition in the
development of polyps in PJS mice [5]. During this trial, rapamy-
cin was given in LKB1 1/2 mice at 9 months of age (after the
onset of polyposis) at the dose of 2 mg/kg per day for a 2-
month period.The efﬁcacy of rapamycin was assessed by meas-
uring polyp sizes and tumor burden. It was found that rapamy-
cin effectively suppresses PJS polyposis in a mouse model,
suggesting that mTOR inhibitors may represent a new targeted
therapy for the treatment of PJS.
Shackelford et al. analyzed 11-month-old LKB1 1/1 and
LKB1 1/2 mice by ﬂudeoxyglucose (FDG)-positron emission
tomography (PET) to scan for the presence of gastrointestinal
(GI) polyps [6]. Images showed increased FDG uptake in focal
masses located in the LKB11/2 mice where the stomach and
pylorus are located, whereas the LKB1 1/1 were negative
(p5 .06) for FDG signal in this area. Several of the LKB1 1/2
mice were killed after imaging, and it was conﬁrmed that these
animals had large polyps in the pylorus and stomach corre-
sponding exactly to the regions of greatest FDG uptake. Treat-
ment of animals with rapamycin for 4 weeks abolished the
FDG-PET signal. Immediate autopsy of the animals imaged by
FDG-PET revealed that the rapamycin-treated mice had mini-
mal detectable GI polyps, whereas the vehicle-treated mice all
exhibited the presence of large GI polyps. These results suggest
that rapamycin reverses polyp growth in LKB11/2mice.
Our study is based on the observation by Franz et al. that
rapamycin, U.S. Food and Drug Administration approved for
use in orthotopic transplant recipients, was successfully used in
an off-label study of ﬁve individuals with tuberous sclerosis [7].
This disease, which is related to PJS, is caused by germline
mutations in the tuberous sclerosis complex 1 or 2, down-
stream of LKB1, also leading to aberrant mTOR activation. All of
the patients in this study had subependymal giant cell astrocy-
tomas, which exhibited regression and necrosis on well-
tolerated treatment with oral rapamycin. Faivre et al. suggested
in 2006 the beneﬁt of mTOR inhibitors in the treatment of
patients with PJS [8]. In a recent case of a patient with PJS suf-
fering from advanced pancreatic cancer, we observed an
impressive response to oral treatment with everolimus mono-
therapy [9]. Therefore, mTOR inhibition might be a potential
anticancer treatment in Peutz-Jeghers-related malignancies
and needs conﬁrmation in a larger patient cohort.
Toxicity: Several trials with everolimus have already been per-
formed. Yee et al. performed a phase I/II study with everolimus
10 mg daily in hematological malignancies and observed the fol-
lowing adverse events in more than 15% of the patients, in
descending order of frequency: anorexia, oral aphthous ulcers,
diarrhea, fatigue, dermatologic, dysgeusia, constipation, and
cramps [10]. Blood tests also showed hyperglycemia, hyperlipid-
emia, elevated hepatic parameters, hypophosphatemia, hypo-
magnesemia, and hypocalcemia in more than 15% of the
patients. Motzer et al. executed a phase III trial in patients with
renal-cell cancer [11]. Stomatitis, rash, fatigue, asthenia, diarrhea,
and anorexia occurred in more than 15% of the participants,
using 10 mg everolimus per day. Most of the aforementioned
adverse events are grade 1 or 2. Toxicities of grade 3 and 4 are
rare, with stomatitis and fatigue in less than 10%. In the latter
study, everolimus toxicity led to treatment discontinuation for
10% of the patients. Furthermore, 34% of the patients required a
dose interruption and 5% had a dose reduction.
Chemoprevention: The use of chemoprophylaxis is not a
new phenomenon. The ability to prevent cancer has been dem-
onstrated before, and some agents are already administrated
for cancer prevention in clinical practice, with aspirin as the
best-known example. Low-dose aspirin is proven to be success-
ful in reducing cancer incidence by about 10% in men and 7%
in women [12]. Because the side-effect proﬁle is favorable, the
beneﬁts of aspirin treatment outweigh the adverse events in
patients without risk factors for gastrointestinal bleeding.
Another chemoprophylactic drug used is tamoxifen, which is
effective against breast cancer [12]. Serious adverse events
such as endometrial cancer and venous thromboembolism are
rare, making this drug suitable for therapeutic prevention in
patients with an elevated breast cancer risk.
In the setting of a preventive intervention with potential
severe adverse events, the selection of high-risk patients is
essential. The presence of a mutation resulting in an enhanced
cancer risk might be a suitable target for chemoprevention.
Squarize et al. investigated the use of a chemopreventive agent
targeting a directly associated mutation, a situation comparable
to the one in our trial [13]. The administration of rapamycin in
mice with the Cowden’s disease mutation resulted in a
decrease of tumor growth and prolonged survival. A chemopre-
vention trial on patients with PJS, executed in 2011, did not
lead to statistical analysis due to insufﬁcient polyp burden and
poor accrual [14].
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